HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Treatment with insulin is associated with worse outcome in patients with chronic heart failure and diabetes.

AbstractAIMS:
Up to one-third of patients with diabetes mellitus and heart failure (HF) are treated with insulin. As insulin causes sodium retention and hypoglycaemia, its use might be associated with worse outcomes.
METHODS AND RESULTS:
We examined two datasets: 24 012 patients with HF from four large randomized trials and an administrative database of 4 million individuals, 103 857 of whom with HF. In the former, survival was examined using Cox proportional hazards models adjusted for baseline variables and separately for propensity scores. Fine-Gray competing risk regression models were used to assess the risk of hospitalization for HF. For the latter, a case-control nested within a population-based cohort study was conducted with propensity score. Prevalence of diabetes mellitus at study entry ranged from 25.5% to 29.5% across trials. Insulin alone or in combination with oral hypoglycaemic drugs was prescribed at randomization to 24.4% to 34.5% of the patients with diabetes. The rates of death from any cause and hospitalization for HF were higher in patients with vs. without diabetes, and highest of all in patients prescribed insulin [propensity score pooled hazard ratio for all-cause mortality 1.27 (1.16-1.38), for HF hospitalization 1.23 (1.13-1.33)]. In the administrative registry, insulin prescription was associated with a higher risk of all-cause death [odds ratio (OR) 2.02, 95% confidence interval (CI) 1.87-2.19] and rehospitalization for HF (OR 1.42, 95% CI 1.32-1.53).
CONCLUSIONS:
Whether insulin use is associated with poor outcomes in HF should be investigated further with controlled trials, as should the possibility that there may be safer alternative glucose-lowering treatments for patients with HF and type 2 diabetes mellitus.
AuthorsFranco Cosmi, Li Shen, Michela Magnoli, William T Abraham, Inder S Anand, John G Cleland, Jay N Cohn, Deborah Cosmi, Giorgia De Berardis, Kenneth Dickstein, Maria Grazia Franzosi, Lars Gullestad, Pardeep S Jhund, John Kjekshus, Lars Køber, Vito Lepore, Giuseppe Lucisano, Aldo P Maggioni, Serge Masson, John J V McMurray, Antonio Nicolucci, Vito Petrarolo, Fabio Robusto, Lidia Staszewsky, Luigi Tavazzi, Roberto Teli, Gianni Tognoni, John Wikstrand, Roberto Latini
JournalEuropean journal of heart failure (Eur J Heart Fail) Vol. 20 Issue 5 Pg. 888-895 (05 2018) ISSN: 1879-0844 [Electronic] England
PMID29488676 (Publication Type: Journal Article, Multicenter Study, Randomized Controlled Trial)
Copyright© 2018 The Authors. European Journal of Heart Failure © 2018 European Society of Cardiology.
Chemical References
  • Hypoglycemic Agents
  • Insulin
Topics
  • Aged
  • Cause of Death (trends)
  • Comorbidity
  • Diabetes Mellitus, Type 2 (drug therapy, epidemiology)
  • Double-Blind Method
  • Female
  • Heart Failure (diagnosis, epidemiology, physiopathology)
  • Humans
  • Hypoglycemic Agents (therapeutic use)
  • Insulin (therapeutic use)
  • Italy (epidemiology)
  • Male
  • Prognosis
  • Propensity Score
  • Registries
  • Risk Factors
  • Survival Rate (trends)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: